EyePoint, Inc. to Host Conference Call on March 4, 2026, to Discuss Q4 and Full-Year 2025 Financial Results

EyePoint, Inc. will host a conference call on March 4, 2026, to discuss 2025 financial results and developments.

Quiver AI Summary

EyePoint, Inc. announced that it will host a conference call and live webcast on March 4, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results, along with recent corporate developments. The company focuses on innovative therapeutics for serious retinal diseases and is currently advancing its lead product candidate, DURAVYU™, in pivotal Phase 3 trials for wet age-related macular degeneration and plans to initiate dosing for diabetic macular edema soon. EyePoint, headquartered in Watertown, Massachusetts, has a history of developing treatments with four approved drugs over three decades, and it is committed to improving patients' lives while driving long-term value. The DURAVYU name has been conditionally accepted by the FDA but remains investigational and unapproved.

Potential Positives

Announcement of an upcoming conference call to report Q4 and full-year 2025 financial results indicates transparency and engagement with investors.
DURAVYU™, the company's lead product candidate, is supported by robust safety and efficacy data from multiple clinical trials, highlighting strong potential for success in the market.
The commencement of Phase 3 pivotal trials for DURAVYU™ signals significant progress in the company's development pipeline, with topline data expected in mid-2026.
EyePoint's commitment to partnering with the retina community demonstrates its dedication to improving patient outcomes and creating long-term value in the ophthalmic field.

Potential Negatives

The press release emphasizes that DURAVYU™, the company’s lead product candidate, is still an investigational product that has not received FDA approval, which raises concerns about its market potential and profitability.
There is uncertainty regarding the timeline for potential FDA approval, creating ambiguity that might deter investors and stakeholders.
The mention of only four approved drugs over three decades may suggest a slower pace of successful product development compared to competitors in the market.

FAQ

What is the date and time of EyePoint's upcoming conference call?

EyePoint's conference call is scheduled for 8:30 a.m. ET on March 4, 2026.

How can I access the live webcast of the conference call?

You can access the live audio webcast via the Investors section of the EyePoint website at www.eyepoint.bio.

What key topics will be discussed during the conference call?

The call will report on EyePoint's fourth quarter and full-year 2025 financial results and recent corporate developments.

What is DURAVYU™ and its significance?

DURAVYU™ is EyePoint's investigational sustained delivery treatment for serious retinal diseases currently undergoing Phase 3 trials.

Is DURAVYU™ approved by the FDA?

DURAVYU™ has not yet been approved by the FDA and is currently in the investigational stage.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$EYPT Insider Trading Activity

$EYPT insiders have traded $EYPT stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $EYPT stock by insiders over the last 6 months:

ASSET MANAGEMENT, LP CORMORANT sold 60,000 shares for an estimated $942,240
RAMIRO RIBEIRO (Chief Medical Officer) has made 0 purchases and 3 sales selling 47,703 shares for an estimated $795,476.
NANCY LURKER has made 0 purchases and 3 sales selling 10,000 shares for an estimated $150,942.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$EYPT Hedge Fund Activity

We have seen 98 institutional investors add shares of $EYPT stock to their portfolio, and 69 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC added 2,937,729 shares (+inf%) to their portfolio in Q4 2025, for an estimated $53,672,308
CITADEL ADVISORS LLC removed 2,135,389 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $39,013,557
BLACKROCK, INC. added 1,823,346 shares (+36.7%) to their portfolio in Q4 2025, for an estimated $33,312,531
PARADIGM BIOCAPITAL ADVISORS LP added 1,686,110 shares (+84.1%) to their portfolio in Q4 2025, for an estimated $30,805,229
SUVRETTA CAPITAL MANAGEMENT, LLC added 1,634,970 shares (+26.4%) to their portfolio in Q4 2025, for an estimated $29,870,901
FEDERATED HERMES, INC. added 1,601,101 shares (+36.3%) to their portfolio in Q4 2025, for an estimated $29,252,115
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,240,218 shares (-18.2%) from their portfolio in Q3 2025, for an estimated $17,660,704

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments.

To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg . A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio . A webcast replay will also be available on the Company website at the conclusion of the call.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU ^™ , is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E ^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU ^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
[email protected] / [email protected]

Media Contact:

Green Room Communications
Direct: 850-384-2833
[email protected]